Product Brochure: Maximize risk mitigation with custom cGMP oligos
28 March 2024

Manufacturing oligonucleotides under cGMP maximizes risk mitigation by minimizing the probability of contamination, mix-ups, deviations, failures, and other errors, which in turn ensure that the oligo products meet the stringent requirements of molecular diagnostics, laboratory developed tests, and preclinical research. In this brochure, Merck highlights the benefits of custom oligos made under these quality and manufacturing systems such as controlled processes, extensive traceability, batch consistency, reproducible results, and scalability. All products are manufactured in compliance with US GMP standards, utilizing classified cleanrooms and maintaining ISO 13485 Quality Management System certification. Custom cGMP oligos are available with various specifications and modifications for applications such as PCR, qPCR, and next-generation sequencing.